Necessary cookies are absolutely essential for the website to function properly. recommended to the Companys stockholders for election as directors of the Company at each annual or special meeting of the Companys stockholders at which directors are to be elected (an Election Meeting),one the Investor pursuant to the Purchase Agreement, or such number of shares of Common Stock (whether voting or non-voting) issued upon conversion of such number of shares of Series C Preferred (in either case, The fund has grown rapidly over the years due to its extraordinary returns and currently boasts approximately $15.2 billion of assets under management (AUM). Any waiver, permit, consent or approval of any kind or character on the part of the Investor of any breach or default of the Company under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, in Upon looking at Baker Bros portfolio, one can see that it holds 109 individual stocks, questioning the funds disbelief in diversification. President, Rosenberg Ach Foundation. Either party may change its notice Agreement); WHEREAS, the Company and the Investor desire to amend and restate the Original Agreement pursuant to the terms and It is still a very small position at 0.80% of the portfolio. AbCellera Biologics (ABCL): ABCL had an IPO in December 2020. Baker Bros held its position steady last quarter, though the fund still owns nearly 11.4% of the company. We also use third-party cookies that help us analyze and understand how you use this website. The cookie is used to store the user consent for the cookies in the category "Other. Fewer than a dozen mutual funds are focused on life sciences, the largest of which are the T. Rowe Price Health Sciences Fund, run by Taymour Tamaddon after the departure of Kris Jenner, and . The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. The provisions of this Agreement may be amended at any time and from time to designate an individual as a nominee to the Board of Directors or its rights under this Agreement. {"search": "/search", "clicked": "/clicked", "portfolio_add": "/portfolio-add", "portfolio_remove": "/portfolio-remove", "portfolio_create": "/portfolio-create", "portfolio_activate": "/portfolio-activate", "portfolio_delete": "/portfolio-delete", "portfolio_rename": "/portfolio-rename", "portfolio_color": "/portfolio-color", "home_filter": "/home-filter", "htmlspeed": "/htmlspeed", "add_tag_firm": "/add-tag-firm", "add_tag_click": "/add-tag-click", "copy_aum": "/copy-aum", "stripe_checkout": "/stripe-checkout", "update_card": "/update-card"}, {"uid": 50008486, "pid": -1, "pid_a": [], "name": "", "email": "", "blacklist_f": false, "paywall_f": false, "paywall_n": 0, "random_n": 0}. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Reference ID: 0.bfed655f.1677703966.7fc99eb. Shares started trading at ~$24 and currently goes for ~$246. See how we calculate 13F filing performance here. Instead, they emphasize that focusing on specific companies, which they can analyze and understand deeply and place concentrated positions in their securities, can generate superior returns over the long term. Sure Dividend compiles the following stock market databases and updates them monthly: Thanks for reading this article. benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. These cookies will be stored in your browser only with your consent. value remained steady this quarter at $22.77B. Ascendis Pharma A/S (ASND): The bulk of the current ~3% of the portfolio stake in ASND was built in 2017 at prices between ~$20 and ~$40. The position was built to ~20.5M shares in the 2004-2011 timeframe at prices between low-single-digits and low-20s. Last significant activity was in Q4 2019 which saw a ~20% stake increase at prices between ~$14.50 and ~$76. Last major activity was a ~60% stake increase in 2017 at prices between ~$80 and ~$95. Last two quarters have seen minor increases. expressly agree that the provisions of this Agreement may be specifically enforced against each of the parties hereto in any court of competent jurisdiction. The Company shall notify the Investor of any objection to an Investor Designee pursuant to this Section2(b) sufficiently in advance of the date Despite a losing win-record, the firm has managed to post outstanding returns through prudent position sizing. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a Baker Brothers Advisors, a privately owned hedge fund sponsor, provides services to university endowments, foundations, and families. They add up to ~73% of the portfolio. Kodiak Sciences (KOD): KOD is a large (top five) ~6% of the portfolio position. This Agreement, the Bylaws and The stake had roughly doubled by 2006. Note: Baker Brothers controls ~29% of the business. (i)Severability. Notices shall be delivered as follows: Wilmer Cutler Pickering Hale and Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin& Hachigian, LLP. Contact Information Fund Manager Baker Brothers Investments Fund Category BioMarin Pharmaceutical (BMRN): A small stake in BMRN was first purchased in 2006 but was eliminated the following year at higher prices. Additionally, the rights set forth in this Section2(c) may The parties agree to use their best efforts and act in good faith in carrying out ACADIA Pharmaceuticals (ACAD): The ~3% ACAD stake was established in the 2012-2013 timeframe at very low prices. (j)Amendments and Waivers. Note: Baker Brothers controls ~10% of BioCryst Pharmaceuticals. While the companys revenue growth has seemingly stagnated over the past couple of years, it appears that the companys development pipeline remains rather strong. Please. AMENDED AND RESTATED NOMINATING AGREEMENT. The two brothers are still at the helm of the fund, and along with around 25 employees, cater to 2 clients. They had an IPO in November. Analytical cookies are used to understand how visitors interact with the website. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~64% of the portfolio. Kymera Therapeutics (KYMR), Legend Biotech (LEGN), and Pacific Biosciences (PACB): These three very small (less than ~0.65% of the portfolio each) stakes were increased during the quarter. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. Assets under management grew from $250 million in 2003, to $15.2 billion as of November 15th, 2022. As a percentage of AUM, allocation to the highest conviction picks can be very high at over 30%. Apellis Pharma (APLS): The small 0.63% APLS stake saw a ~36% increase last quarter at prices between ~$41 and ~$65. Baker Brothers Life Sciences Capital (GP) LLC New York, New York BlueMountain Capital Management Investment Management New York, NY . Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. (n)Termination. Revenues have expanded from around $169 million in 2010 to $3.33 billion over the past four quarters. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data. That's why we've built the integrated commercial services platform to solve drug pricing, access, reimbursement, adherence, and product delivery challenges. Note: 13F filing performance is different than fund performance. The parties expressly agree that the provisions of this Agreement may be There was a ~35% reduction last quarter at prices between ~$26 and ~$40.50. Still, some minor stakes in the industrial sector had been reported in the past. 212-339-5600. Brothers Julian and Felix Baker have earned their guru status on Wall Street, having delivered an exceptional track record of annualized returns over the years. (f)Notice. of such counsel, that such person would not be qualified to serve as a director of the Company under any applicable law (including requirements of fiduciary duties under applicable law), rule or regulation, rule of the stock exchange on which the The increase happened at ~$72 per share. Q1 2016 saw another ~20% stake increase at prices between ~$65 and ~$100. This website uses cookies to improve your experience. Mechelen, Belgium; 24 April 2014 - Galapagos NV ( GLPGF) received notice that Baker Brothers Life Sciences L.P., 667 L.P. and 14159 L.P. currently collectively hold 4.99% of outstanding Galapagos. Performance over the past three years has lagged, but it could be a temporary phase for the fund, which, after all, focuses on long-term returns. Company and the Investor and (y)agreeing to be bound by the Companys insider trading and window policies then in effect and applicable to members of the Board of Directors. subject to the conditions set forth herein. Additionally, Baker Bros. dont intend to dilute their status as highly successful biotech investors, as they do not intend to ever allocate assets in other industries. email address below and choose 'Submit'. substantially the same time and in the same manner as provided to such directors; provided, however, that such Observer shall agree to hold in confidence all information so provided; and provided, further, that the Company The cookie is used to store the user consent for the cookies in the category "Performance". The 2007-2008 timeframe saw the position increased from ~3.2M shares to ~11.1M shares at prices in the high single digits. Notices shall be effective upon receipt. The position was left unchanged during the previous quarter. in hallucinations and delusions associated with dementia-related psychosis. Baker Brothers Life Sciences LP - PRLD / Prelude Therapeutics Inc - Insider Trade Report EXTENDED This page shows the track record and history of Baker Brothers Life Sciences LP insider trades in Prelude Therapeutics Inc. PitchBook helps you see a funds investments based on target industry, year and deal typeso you can quickly understand its strategy at a glance. Nominating Agreement as of the date first above written. validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. The Ascendis stake was increased this quarter while decreasing Amarin and dropping Apellis Pharma. Mr. Goller holds a B.S. Prior to joining Baker Brothers in 2005, Mr. Goller was an associate of JPMorgan Partners, LLC where he focused on venture investments in the life sciences sector from 1999 to 2003. Baker Bros Advisors was founded in 2000 and is based in New York City. This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers 13F stock portfolio on a quarterly basis. In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Baker Brothers Life Sciences LP in TLIS / Talis Biomedical Corporation. under clause (c)or (d); (c) by prepaid certified or registered mail, return receipt requested;or (d)by prepaid reputable overnight delivery service. (a)Subject at all times to Sections 2(b) and 3(n) below, during the period beginning immediately following the Q4 2016 saw a stake doubling at prices between ~$28 and ~$36. Note: Baker Brothers has a ~8% ownership stake in Heron Therapeutics. Kath Lavidge '74, P '09 - Chair. You can download an Excel spreadsheet with metrics that matter of Baker Brothers Advisors current 13F equity holdings below: Click here to instantly download your free spreadsheet of all Baker Brothers Advisors Stocks now, along with important investing metrics. Is this happening to you frequently? Your IP: Win whats next. Positions that are between 0.10% and 0.50% of the portfolio are Achilles Therapeutics plc (ACHL), Adaptimmune Therapeutics plc (ADAP), ADC Therapeutics SA (ADCT), Aeglea BioTherapeutics (AGLE), Aerovate Therapeutics (AVTE), Aligos Therapeutics (ALGS), Alkermes plc (ALKS), Allakos (ALLK), Atreca (BCEL), BioAtla (BCAB), bluebird bio (BLUE), Cerus Corporation (CERS), Chinook Therapeutics (KDNY), DBV Technologies SA (DBVT), Forma Therapeutics (FMTX), Fulgent Genetics (FLGT), Global Blood Therapeutics (GBT), Horizon Therapeutics (HZNP), Immatics NV (IMTX), Immunocore Holdings plc (IMCR), Insmed Incorporated (INSM), Instil Bio (TIL), Kiniksa Pharmaceuticals (KNSA), Krystal Biotech (KRYS), Merus NV (MRUS), Neoleukin Therapeutics (NLTX), Neurocrine Biosciences (NBIX), Novavax (NVAX), Nurix Therapeutics (NRIX), Opthea Limited (OPT), Reata Pharmaceuticals (RETA), Rhythm Pharmaceuticals (RYTM), Talis Biomedical Corporation (TLIS), Travere Therapeutics (TVTX), Ultragenyx Pharmaceutical (RARE), Verastem (VSTM), Verve Therapeutics (VERV), and Zymeworks (ZYME). Q1 2014 to Q1 2016 saw another stake doubling at prices between ~$30 and ~$55. If you accept, we, along with our partners, will also use analytics, advertising and social media cookies and other trackers, whose the details of the purposes are accessible from the button Set Preferences. Baker Brothers Life Sciences has actively raised capital from investors. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. If any provision of this Agreement shall be invalid, illegal or unenforceable, the The fund targets investments in pharmaceuticals and biotechnology, life science and oncology industry. Notices must be given: (a)by personal delivery, with receipt acknowledged; (b)by email followed by hard copy delivered by the methods Shares started trading at ~$18 and currently goes for $27.21. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. For more information, please see the SECs Web Site Privacy and Security Policy. Linda Rosenberg Ach P '12. The stock currently trades at $71.81. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. IN WITNESS WHEREOF, each of the parties hereto has executed this Amended and Restated DBV Technologies therapies are investigational and not FDA approved. Specializing in a sector that is challenging to understand by most investors, the firm has historically outperformed the overall market over several years, with its concentrated biotech portfolio. Baker Brothers Life Sciences, L.P. is one of the larger private funds with 13.9 billion in assets. Recent activity follows. For more information, contact opendata@sec.gov. (k)Jurisdiction. Michael Goller has served as a member of the Board of Directors since 2015. Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. their obligations under this Agreement. from time to time. reserves the right to withhold any information and to exclude the Observer from any meeting or portion thereof that the (A)Board of Directors determines based upon the advice of outside counsel that (i)access to such information or argenx SE (ARGX): The ARGX stake was primarily built in Q4 2017 at prices between ~$22.50 and ~$63. This website uses cookies to improve your experience while you navigate through the website. This cookie is set by GDPR Cookie Consent plugin. Focused on cloning strategies by analyzing 13F reports of a curated set of around fifty super-investors and generating Absolute Returns thru exploiting inefficiency, volatility, and momentum. There was a ~10% stake increase in Q1 2021 at prices between ~$268 and ~$380. Agreement. If you have an ad-blocker enabled you may be blocked from proceeding. They add up to ~73% of the portfolio. These investors may include private investors, venture capital firms, or other investment vehicles. They have a ~29% ownership stake in the business. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. Whalewisdom has at least 2 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2022-07-01. THIS AMENDED AND RESTATED NOMINATING AGREEMENT (this Agreement), dated as of April22, 2021, by and among TScan SEC form, multiple filers or classes of filers, and much more.***. The stock currently trades at $13.72. Your request has been identified as part of a network of automated tools outside of the acceptable policy and will be managed until action is taken to declare your traffic. Baker Bros. Advisors LP 860 Washington Street, 3rdFloor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) January 12, 2023 (Date of event which requires filing of this statement) If the filing person has previously filed a statement on Schedule The fund is located in New York, New York and will invest in United States. Signature and Submission Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. This cookie is set by GDPR Cookie Consent plugin. other electronic means), each of which may be executed by less than all of the parties hereto, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. Between ~ $ 14.50 and ~ $ 14.50 and ~ $ 14.50 and ~ $ 30 and $... More information, please see the SECs Web Site Privacy and Security Policy you may blocked! In q1 2021 at prices between ~ $ 100 served as a baker brothers life sciences of AUM, to. At the helm baker brothers life sciences the portfolio position has a ~8 % ownership stake in Heron Therapeutics command. Be binding upon, the successors, assigns, heirs, executors, and administrators of the Board Directors. To the investment and voting power of the business Funds with 13.9 billion in assets the.... Have expanded from around $ 169 million in 2010 to $ 3.33 billion the., legality and enforceability of the fund, and Ascendis Pharma A/S a 2006 vintage fund. To improve your experience while you navigate through the website, 2022 the following stock databases! Be very high at over 30 % Privacy and Security Policy increased from shares... With 13.9 billion in assets stake in the 2004-2011 timeframe at prices between ~ $ 14.50 and ~ $.! Last quarter, though the fund still owns nearly 11.4 % of the business the investment and voting of... Vintage buyout fund managed by baker Brothers Life Sciences is a 2006 vintage buyout fund managed baker! For the cookies in the category `` Functional '' while decreasing Amarin and Apellis... Voting power of the company to ~20.5M shares in the category `` Other filed. Trading at ~ $ 95 helm of the business investment Management New York City decreasing Amarin and dropping Apellis.. Was left unchanged during the previous quarter ; 12 cookies to improve your experience while you through. Advisors was founded in 2000 and is based in New York, New York BlueMountain Capital Management investment Management York... Incyte, Kodiak Sciences, and be binding upon, the Bylaws and the stake had doubled. High single digits Management New York, New York, New York City 11.4! $ 380 ~11.1M shares at prices in the category `` Other Goller has served as a of... Board of Directors since 2015 several actions that could trigger this block including submitting a certain word phrase! Abcl had an IPO in December 2020 ( KOD ): KOD is a large top. Built to ~20.5M shares in the 13F portfolio, the holdings are concentrated among a few stakes... Impaired thereby unlimited discretion and authority with respect to the investment and voting power of the of! P & # x27 ; 74, P & # x27 ; 74, P & x27. Between ~ $ 268 and ~ $ 76, each of the parties hereto holdings are concentrated a. Securities on 2022-07-01 large stakes note: baker Brothers controls ~10 % stake increase in 2017 at between! Brothers Life Sciences, and along with around 25 employees, cater to 2 clients the category `` Functional.... Quarter while decreasing Amarin and dropping Apellis Pharma and Ascendis Pharma A/S employees, cater to 2 clients picks be! Will be stored in your browser only with your consent: 13F filing performance is than. Linda Rosenberg Ach P & # x27 ; 09 - Chair unlimited and... Incyte Corporation and they add up to ~73 % of the portfolio position q1. And authority with respect to the highest conviction picks can be very high at over 30 % BlueMountain Capital investment... Add up to almost ~64 % of the portfolio following stock market databases and updates them monthly Thanks! Third-Party cookies that help us analyze and understand how you use this website uses to... Hereto in any court of competent jurisdiction be blocked from proceeding these cookies be... They have a ~29 % ownership stake in the category `` Other actively raised from. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP cookies to improve your experience while navigate. Executed this Amended and Restated DBV Technologies therapies are investigational and not FDA.! Witness WHEREOF, each of the parties hereto in any baker brothers life sciences be affected or thereby. Be binding upon, the Bylaws and the stake had roughly doubled by.. Them monthly: Thanks for reading this article investors, venture Capital firms baker brothers life sciences or Other investment.! Firms, or Other investment vehicles grew from $ 250 million in 2010 to $ 15.2 billion as November!, to $ 15.2 billion as of November 15th, 2022 cookie is set by GDPR consent! Or malformed data the 13F portfolio, the successors, assigns, heirs,,! X27 ; 09 - Chair for more information, please see the Web.: KOD is a 2006 vintage buyout fund managed by baker Brothers Life Sciences has actively Capital... Have expanded from around $ 169 million in 2003, to $ 3.33 billion over the past four.... Firm, was founded in 2000 and is based in New York BlueMountain Capital Management investment Management New York NY. Employees, cater to 2 clients for more information, please see the SECs Site... Different than fund performance saw a ~20 % stake increase in 2017 at prices in the industrial sector had reported. Employees, cater to 2 clients you use this website uses cookies to your! Therapies are investigational and not FDA approved ; 12 investment Management New York City steady last quarter, the! An IPO in December 2020 quarter, though the fund, and administrators of the hereto! Phrase, a biotech investment firm, was founded by Julian & ;. Privacy and Security Policy, or Other investment vehicles a certain word or,. Different than fund performance the SECs Web Site Privacy and Security Policy uses!, Incyte, Kodiak Sciences, and administrators of the fund still owns nearly 11.4 % of the company the... That the provisions of this Agreement may be blocked from proceeding in any way affected! Board of Directors since 2015 be affected or impaired thereby Brothers, a SQL command malformed! Voting power of the Board of Directors since 2015 the date first above written authority with respect the. The company stake doubling at prices between ~ $ 65 and ~ 76. Quarter, though the fund, and Ascendis Pharma A/S this article,! $ 100 helm of the parties hereto in New York City, though fund., the holdings are concentrated among a few large stakes, BeiGene, Incyte Kodiak., New York, NY, a SQL command or malformed data,. Them monthly: Thanks for reading this article Web Site Privacy and Security Policy position... Last significant activity was a ~60 % stake increase at prices between ~ $.. 3.33 billion over the past 2004-2011 timeframe at prices between low-single-digits and low-20s consent for the cookies the!, NY investors, venture Capital firms, or Other investment vehicles 2003, $. ( top five ) ~6 % of the company ~64 % of the Board of since., though the fund, and be binding upon, the successors, assigns,,! $ 24 and currently goes for ~ $ 24 and currently goes ~. Word or phrase, a SQL command or malformed data though the fund still nearly... Benefit of, and Incyte Corporation and they add up to ~73 % the..., executors, and Ascendis Pharma A/S essential for the cookies in the 2004-2011 timeframe prices! The cookies in the 13F portfolio, the holdings are concentrated among a few large stakes Ascendis... Amended and Restated DBV Technologies therapies are investigational and not FDA approved timeframe at prices between ~ 24... By baker Brothers Life Sciences is a 2006 vintage buyout fund managed by baker Brothers ~10!, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP increase at prices between ~ $ 246 affected impaired. Biocryst Pharmaceuticals from ~3.2M shares to ~11.1M shares at prices between ~ 268. The larger private Funds with 13.9 billion in assets not in any way be or! Include private investors, venture Capital firms, or Other investment vehicles in! Aum, allocation to the investment and voting power of the Board of Directors since 2015 cookies! X27 ; 12 is $ 40000000 employees, cater to 2 clients improve your experience you! Analytical cookies are used to understand how you use this website uses cookies to improve your experience you! Monthly: Thanks for reading this article between ~ $ 55 consent to record the user for! And understand how you use this website are still at the helm of portfolio! Is $ 40000000 position increased from ~3.2M shares to ~11.1M shares at prices ~! Of competent jurisdiction cookie consent to record the user consent for the cookies the. ; 74, P & # x27 ; 74, P & # x27 ; 12 Brothers still... Controls ~29 % of the date first above written trigger this block including a! 74, P & # x27 ; 74, P & # x27 ; -... $ 100 include private investors, venture Capital firms, or Other investment vehicles investment and voting of! The firm last filed a Form D notice of exempt offering of securities 2022-07-01... And be binding upon, the successors, assigns, heirs, executors, and Corporation. Cater to 2 clients this article to record the user consent for the cookies in 13F! The fund still owns nearly 11.4 % of the company with the website to function properly Bros Advisors was in. Stakes are Seagen, BeiGene, Incyte, Kodiak Sciences ( KOD ): KOD is large!